In fact, although inhibitors of canonical survival pathways, such as BCR signaling, BCL2 and PI3K/AKT are being evaluated in distinct molecular subsets of DLBCL, there are currently no clinically approved targeted therapeutic strategies for OxPhos-type tumors [59–61], highlighting an unmet therapeutic need. This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.